Skip to content

Saxagliptin upregulates nesfatin-1 secretion in type 2 diabetes mellitus: a 52-week controlled trial

Saxagliptin upregulates nesfatin-1 secretion in type 2 diabetes mellitus: a 52-week controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OON-17011950
Enrollment
Unknown
Registered
2017-07-11
Start date
2012-02-22
Completion date
Unknown
Last updated
2017-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes

Interventions

Control:None DPP-4 Inhibitors

Sponsors

Jiangsu Jiankang Vocational College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
49 Years to 74 Years

Inclusion criteria

Inclusion criteria: Diabetes were diagnosed in accordance with criteria as following: fasting glucose level = 7.0 mmol/L or 2-h postprandial plasma glucose level = 11.1 mmol/L

Exclusion criteria

Exclusion criteria: Participants who with a history of established cardiovascular disease (patients at least 40 years old and had a history of a clinical event associated with atherosclerosis involving coronary, cerebrovascular or peripheral vascular system) or abnormal function of kidney or liver were excluded.

Design outcomes

Primary

MeasureTime frame
nesfatin-1;

Countries

China

Contacts

Public ContactKuanlin CHEN

Jiangsu Jiankang Vocational College

53972178@qq.com+86 13376071599

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026